Literature DB >> 6691350

Candidal infection in the central nervous system.

S A Lipton, W F Hickey, J H Morris, J Loscalzo.   

Abstract

Candida has become the most prevalent cerebral mycosis at autopsy, indicating a significant incidence coupled with inadequate eradication. Of 29 patients with systemic candidiasis, 48 percent (14 of 29) also had central nervous system involvement. Of these patients, however, only 21 percent (three of 14) had antemortem diagnosis, and only one of these three patients remains alive; the two patients with antemortem diagnosis who died had a meningeal form that, although easier to document on the basis of cerebrospinal fluid examination, is now distinctly rarer than other forms of the disease in adults. The lone surviving patient was treated with amphotericin B for endocarditis and mycotic aneurysms of the cerebral vessels. One clue to central nervous system candidal infection was the striking correlation between cardiac and cerebral involvement; 80 percent of patients with myocardial or valve infection also had central nervous system candidiasis. Most forms of immunosuppression represent a risk factor for both the systemic and cerebral mycoses. Neuropathologically, there is a spectrum of disease entities associated with Candida, including two previously unrecognized lesions reported herein: fungus balls of both white and gray matter and mycotic aneurysms secondary to Candida parapsilosis. Other parenchymal presentations include thrombosis, vasculitis, abscess, hemorrhage, and demyelination. For drug therapy such as amphotericin B to be more effective, earlier diagnosis of these parenchymal infections must be sought.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6691350     DOI: 10.1016/0002-9343(84)90757-5

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  19 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

2.  Canadian clinical practice guidelines for invasive candidiasis in adults.

Authors:  Eric J Bow; Gerald Evans; Jeff Fuller; Michel Laverdière; Coleman Rotstein; Robert Rennie; Stephen D Shafran; Don Sheppard; Sylvie Carle; Peter Phillips; Donald C Vinh
Journal:  Can J Infect Dis Med Microbiol       Date:  2010       Impact factor: 2.471

3.  Polymicrobial central nervous system infection in the acquired immunodeficiency syndrome.

Authors:  A D Sperber; M Alkan; S Stemmer; L Avnon; F Schlaeffer
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-07       Impact factor: 10.154

Review 4.  Candidiasis.

Authors:  F Meunier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-05       Impact factor: 3.267

5.  Adhesion of Candida albicans to brain tissue of Macaca mulata in an ex vivo assay.

Authors:  F J Denaro; J L López-Ribot; W L Chaffin
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

Review 6.  Candida parapsilosis, an emerging fungal pathogen.

Authors:  David Trofa; Attila Gácser; Joshua D Nosanchuk
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

7.  Protective effect of picolinic acid on mice intracerebrally infected with lethal doses of Candida albicans.

Authors:  E Blasi; R Mazzolla; L Pitzurra; R Barluzzi; F Bistoni
Journal:  Antimicrob Agents Chemother       Date:  1993-11       Impact factor: 5.191

8.  Differential host susceptibility to intracerebral infections with Candida albicans and Cryptococcus neoformans.

Authors:  E Blasi; R Barluzzi; R Mazzolla; F Bistoni
Journal:  Infect Immun       Date:  1993-08       Impact factor: 3.441

9.  Management of deep Candida infection in surgical and intensive care unit patients. British Society for Antimicrobial Chemotherapy Working Party.

Authors: 
Journal:  Intensive Care Med       Date:  1994-08       Impact factor: 17.440

Review 10.  Candida parapsilosis endocarditis: a comparative review of the literature.

Authors:  C Garzoni; V A Nobre; J Garbino
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12       Impact factor: 3.267

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.